Navigation Links
Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Date:9/16/2008

rmation about Rebif(R), please visit http://www.mslifelines.com for prescribing information.

* The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

About Merck Serono and multiple sclerosis

Merck Serono is a leader in multiple sclerosis (MS) with Rebif(R) (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of MS, which is registered in more than 80 countries worldwide. Full prescribing information for this product can be obtained by contacting the Company or visiting its website. Additional therapeutic options are currently under development at Merck Serono, including oral cladribine, currently in Phase III and potentially the first oral therapy for MS, as well as several products in early stage development. Merck Serono also is taking a leading role in developing an understanding of the role of genetics in MS.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. The World Health Organization estimates that up to 2.5 million people suffer from MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands s
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
2. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
3. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
9. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
10. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... , , , CARLSBAD, Calif., ... today its intention to file a Special Protocol Assessment (SPA) with ... on its lead drug, DCCR, for the treatment of very high ... primary efficacy endpoint assessed at 12 weeks. This decision followed ...
... , , , ... ANDS ) today announced viral load data for the final cohort of ... Company,s oral inducer of endogenous interferons that acts via the toll-like receptor ... other day over 10 days, the mean (+/-SEM) maximal decline in viral ...
Cached Medicine Technology:Essentialis to Submit SPA for Hypertriglyceridemia 2ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 2ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 3ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 5
(Date:4/24/2014)... of hematopoietic stem cells from cord blood ... from adults, HSCs isolated from cord blood (CB) ... hematological reconstitution when engrafted in children with hematological ... HSCs are present in single CB collections, limiting ... decades investigators have used a variety of strategies ...
(Date:4/24/2014)... better understanding of drug interactions, which are a major ... two or more medications are taken at the same ... the other. Similarly, one drug may magnify the ... major cause of illness and hospitalization. However, there ... drug studies in humans. Limits come in part ...
(Date:4/24/2014)... patients before, during and after colorectal surgery cut hospital ... to researchers who led a study of the approach ... recovery, is easier on patients before surgery, doing away ... typically prescribed. After surgery, patients are encouraged to eat ... faster recoveries. , Among findings published in the May ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... University researcher has found a relationship between motor skill ... spectrum disorder in very young children. , The ... a direct relationship between motor skills and autism severity, ... should be included in treatment plans for young children ... OSU,s College of Public Health and Human Sciences. ...
Breaking Medicine News(10 mins):Health News:JCI online ahead of print table of contents for April 24, 2014 2Health News:JCI online ahead of print table of contents for April 24, 2014 3Health News:JCI online ahead of print table of contents for April 24, 2014 4Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Motor skill deficiencies linked to autism severity in new research 2
... PLC ), a company focused on innovative cardiac ... the three,and six month periods ended June 30, 2008., ... with,$1,932,000 in the second quarter of 2007. The net ... $0.02 per diluted share, compared to a net,loss of ...
... Quigley,Corporation (Nasdaq: QGLY ) today announced that Gerard ... who will be retiring from the Company on,September 5, ... a,member of the Board of Directors. Mr. Gleeson joined ... positions including,Corporate Controller of the Company since 2004., ...
... Aug. 6 China Healthcare,Acquisition Corp (Amex: ... Huadu,Environment Holding Pte, Ltd. ("EAHE") announced today that ... acquisition agreement for CHM to acquire,EAHE in exchange ... the,People,s Republic of China ("China"), Europe-Asia Huadu (Yixing),Environment ...
... useparticularly consumption of beeris declining in the US, according to ... The American Journal of Medicine . Researchers examined 50 ... but no change in alcohol use disorders. Americans are drinking ... has remained fairly constant. More people now report that they ...
... ACG is a team of former medical device sales executives who ... is designed to address the hospital,s current issues with a focus ... declining and it is imperative that savings increase on all hospital ... ...
... discrimination from their health care providers were less likely ... to a report in the August issue of ... the American Association for Cancer Research. , "We ... serious public health implications as we know that higher ...
Cached Medicine News:Health News:PLC Systems Reports Second Quarter 2008 Results 2Health News:PLC Systems Reports Second Quarter 2008 Results 3Health News:PLC Systems Reports Second Quarter 2008 Results 4Health News:PLC Systems Reports Second Quarter 2008 Results 5Health News:PLC Systems Reports Second Quarter 2008 Results 6Health News:The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director 2Health News:China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd. 2Health News:China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd. 3Health News:China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd. 4Health News:China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd. 5Health News:China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd. 6Health News:Alcohol consumption declining, according to results of new study 2Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 2Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 3Health News:Perceived discrimination affects screening rates 2
... proven to be a successful alternative ... knee arthroplasty with proper indications. The ... unicompartmental knee system developed to streamline ... latest conservative surgical techniques with the ...
... Knee CR system was designed to ... femoral joint has a recessed, deepened ... advancement of the patella, which has ... The anatomic groove promotes more normal ...
The Biopro Modular TKO implant is among the thinnest bone conserving Posterior Cruciate Ligament sparing knees available. It provides all the benefits of the Biopro TKO implant and gives the option o...
... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
Medicine Products: